✦ LIBER ✦

A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris

✍ Scribed by Gottlieb, AB; Krueger, J; Lebwohl, M; Gisoldi, E; Grossman, RM; Wacholtz, MC

Book ID: 122648924
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 190 KB
Volume: 16
Category: Article
ISSN: 0923-1811
DOI: 10.1016/S0923-1811(98)84234-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-CD4 monoclonal antibody treatment o

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study

✍ Alice B. Gottlieb; Mark Lebwohl; Sophie Shirin; Amelia Sherr; Pat Gilleaudeau; G 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 577 KB

Efficacy and safety of itolizumab, a nov

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 694 KB

Efficacy and safety of secukinumab in th

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

✍ Papp, K.A.; Langley, R.G.; Sigurgeirsson, B.; Abe, M.; Baker, D.R.; Konno, P.; H 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Moderate to Severe Asthma

✍ Busse, William W.; Holgate, Stephen T.; Kerwin, Edward M.; Chon, Yun; Feng, Jing 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Safety and efficacy of subcutaneous cert

Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFα monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub